Live Breaking News & Updates on Hypoxia Inducible Factor|Page 5
Stay updated with breaking news from Hypoxia inducible factor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers have identified a drug that could be improve recovery after a heart attack in people with diabetes and reduce their risk of developing heart failure ....
Frontiers | Case Report: Can Inhaled Adenosine Attenuate COVID-19? frontiersin.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from frontiersin.org Daily Mail and Mail on Sunday newspapers.
Search jobs Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, and the first patient was dosed with AB308 in combination with zimberelimab Presented promising PFS and OS data for etrumadenant in the ≥3L metastatic colorectal cancer setting at AACR Initiated the randomized portion of our ARC-8 study evaluating AB680, our first-in-class small molecule CD73 inhibitor, in pancreatic cancer following rapid completion of enrollment of the dose-expansion portion of the study Presented preclinical data on a novel series of HIF-2α ....
Analysis: Since it was formally recognised in 1993, the chronic allergic disease Eosinophilic Oesophagitis has become increasingly prevalent in Ireland and around the world, and heavily impacts the quality of life for patients diagnosed. Food allergies as well as other allergic disorders are increasing worldwide year-on-year and what were once deemed rare allergic diseases are becoming more prevalent. Eosinophilic Oesophagitis (EoE) is an emerging chronic allergic disease of the oesophagus and is more recognised now as an increasing clinical problem, affecting as many as 16 in 100,000 people in Europe. Although EoE is a rare disease, its prevalence is increasing since its discovery approximately 20 years ago. It was first described in 1993 by an Irish trained surgeon Dr Stephen Attwood and his colleagues in the United States. ....
Search jobs 10-Apr-2021 Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate etrumadenant-zimberelimab combinations in the 2L, 3L and ≥3L+ mCRC settings Our novel series of HIF-2α inhibitors, including AB521, a highly-potent molecule with a favorable pharmacokinetic profile, has been described for the first time; we remain on track to initiate clinical development for this program in 2H:21 ....